ChemoCentryx, the next Silicon Valley initial public offering expected to debut on Nasdaq this week, lowered its IPO target early on Wednesday.
The Mountain View-based biopharmaceutical company has amended its IPO terms to 4.5 million shares at an offering price of $10 per share.
No comments:
Post a Comment